ZD03 Capsule Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-06

Study Completion Date

2020-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, Double Blind, Randomized, Placebo Controlled, Single Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZD03 Capsule in Healthy Volunteers in The United States

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Study of 3D229 in Healthy Subjects

NCT04941313

Healthy Subject

COMPLETED PHASE1

Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants

NCT05107336

Healthy Participants

COMPLETED PHASE1

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

NCT05794516

Healthy Volunteers

COMPLETED PHASE1

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

NCT05613387

Overweight Healthy Volunteers Obese

COMPLETED PHASE1

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06453824

Safety and Tolerability

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ZD03 is a novel small molecular drug. It is a synthetic chemical drug candidate for treatment of multiple sclerosis (MS) and is proposed to be administered orally as capsules.

This is a double-blind, randomized, placebo-controlled, single ascending dose study. Approximately 56 HVs will enter into the phase 1 study. The study is designed to evaluate the safety,tolerability and PK of ZD03 capsule at different dose cohorts when administered orally.

Subjects who meet the enrollment criteria will be enrolled in one of the seven dose levels designated for the study, including the doses of 20, 40, 80, 120, 180, 240 and 300 mg (doses escalated by 100%, 100%, 50%, 50%, 33% and 25%, respectively). Each cohort will consist of 8 subjects randomized at 3:1 to receive a single oral dose of ZD03 (n=6) or placebo (n=2) in a double-blind manner in a fasted state

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Cohort 1, Dose 1 of ZD03 or Placebo

Dose 1 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 2, Dose 2 of ZD03 or Placebo

Dose 2 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 3, Dose 3 of ZD03 or Placebo

Dose 3 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 4, Dose 4 of ZD03 or Placebo

Dose 4 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 5, Dose 5 of ZD03 or Placebo

Dose 5 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 6, Dose 6 of ZD03 or Placebo

Dose 6 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Experimental: Cohort 7, Dose 7 of ZD03 or Placebo

Dose 7 of ZD03 or matching Placebo capsules by mouth

Group Type EXPERIMENTAL

ZD03

Intervention Type DRUG

ZD03 capsule

Placebo

Intervention Type OTHER

placebo capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZD03

ZD03 capsule

Intervention Type DRUG

Placebo

placebo capsule

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female volunteers aged 18 to 55 years, inclusive.
2. An attempt will be made to recruit at least 50% non-Hispanic Caucasians in each cohort,Healthy (no clinically significant health concerns), as determined by medical history, physical examination, 12-lead ECG, and vital signs at screening.
3. Subjects must have a Body Mass Index (BMI) between 18.0 and 30.0 kg/m2 at screening (inclusive) and weighed a minimum of 50 kg (110 lbs).
4. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal ligation, Essure procedure, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or postmenopausal for ≥ 12 months. The site will attempt to retrieve medical records to document sterility; however, the absence of records will not exclude screening the subject. If medical records cannot be obtained, a negative pregnancy test at screening will be accepted. Postmenopausal status will be confirmed through testing of FSH (follicle stimulating hormone) levels by PI discretion at screening for amenorrhoeic female subjects.

Males must be surgically sterile (\> 30 days since vasectomy with no viable sperm), abstinent or if engaged in sexual relations with a female partner of child-bearing potential, the subject must be using a condom with spermicide from Screening and for a period of 30 days after the last dose of Study Drug.

Acceptable methods of contraception for males are condoms with spermicide.
5. Subjects must have a complete blood count (CBC) and platelet count within the normal range or considered not clinically significant by the PI.
6. Subjects must have normal blood chemistry or results considered not clinically significant by the investigator including electrolytes (Na+, K+, Ca++, and Cl-), alkaline phosphatase, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, uric acid, creatinine, blood urea nitrogen (BUN), and glucose.
7. Subjects must have a normal urinalysis or results considered not clinically significant by the investigator including a normal protein/creatinine ratio per local lab reference ranges (\< 200 mg/g) and a urine creatinine result that does not exceed 300 mg/dL.
8. Subjects must have estimated glomerular filtration rate (eGFR) ≥ 90 mL/min(Based on MDRD).
9. Subjects must have a normal ECG or results considered not clinically significant by the PI.
10. Subjects must be able to comply with the study and follow-up procedures.
11. Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study

Exclusion Criteria

1. Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, including latent tuberculosis, cardiovascular, gastrointestinal including cholecystectomy, neurologic, hepatic, renal, urological, or psychiatric disorders.
2. Subjects who have any history or suspicion of kidney stones.
3. Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B surface antigen, Hepatitis C virus, and/or treponema pallidum.
4. Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days before Day 1 of study medication dosing. Females who have received hormone replacement therapy (HRT) within 28 days prior to dosing.
5. Subjects who have undergone major surgery within 3 months prior to Day 1.
6. Women who are pregnant or breastfeeding.
7. Subjects who received any investigational test article within 5 half-lives or 30 days, whichever is longer, prior to Day 1 study medication dosing.
8. Subjects who consumed Seville oranges or grapefruit containing foods or beverages within 7 days before Day 1 and during the entire study duration.
9. Subjects who had been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication and that in the Investigator's judgment may have impacted subject safety or the validity of the study results.
10. Subjects who had a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.
11. Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes